Revolution Medicines, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RVMD research report →
Range $179 – $350
Price Chart
About the company
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers.
- CEO
- Mark A. Goldsmith
- IPO
- 2020
- Employees
- 883
- HQ
- Redwood City, CA, US
AI snapshot
Six angles, distilled from the data.
The stock remains in a long-term uptrend but has pulled back from its 52-week high of 224.31 and is now trading near the 200-day moving average rather than in a clean breakout. That keeps the regime constructive, but the setup is more consolidation than momentum chase after a sharp run.
Street sentiment stays firmly positive: 22 Buy, 2 Hold, and 0 Sell, with a consensus Buy and an average target of 257.59 versus a 350 high. Recent updates have mostly reiterated bullish calls and nudged targets higher, which supports the longer-term story even after the pullback.
The earnings profile is still uneven, with 1 beat in the last 8 quarters and a recent pattern of misses before the latest 18.8% EPS beat. Next-year EPS is still expected to improve from -9.13 TTM to -3.1521, so shareholders should watch for execution on loss narrowing and pipeline progress.
Recent insider activity leans to net selling, but much of the volume is tied to automatic award/vesting or exempt transactions rather than clear discretionary conviction. The notable signal is that officers and a director were active on the sell side, so the pattern looks more like monetization than accumulation.
Profitability remains deeply negative, with a gross margin of -634.6% and a net loss profile that still weighs on returns. Revenue is also down sharply year over year at -95.2%, but the balance sheet is strong with $2.03 billion in cash and net cash of $1.87 billion.
RVMD sits in the higher-risk, higher-upside tier of biotech: no profits today, but a large cash cushion and a late-stage oncology pipeline. Valuation is rich versus the sector, with a market cap of $34.48 billion and a consensus target of 257.59 above the current share price.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $34.87B
- P/E
- -17.78
- Fwd P/E
- 259.37
- PEG
- 0.36
- P/S
- 178.12
- P/B
- 14.56
- EV/EBITDA
- -19.84
- Div Yield
- 0.00%
- Gross Margin
- 95.16%
- Op Margin
- -852.98%
- Net Margin
- -946.82%
- ROE
- -91.93%
- ROIC
- -43.86%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-16,558,000+0.0%
- Op Income
- $-1,182,369,000
- Net Income
- $-1,131,301,000-88.5%
- EPS
- $-5.95-66.2%
- OCF Growth
- -61.0%
- FCF Growth
- -60.9%
- 52W High
- $224.31
- 52W Low
- $69.50
- 50D MA
- $190.87
- 200D MA
- $161.19
- Beta
- 1.43
- RSI (14)
- 36
- Avg Volume
- 2.24M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Revolution Medicines reported an early but strong U.S. launch for Daraxonrasib, with $198 million in Q3 revenue and broad clinical/commercial momentum across pancreatic cancer and the rest of its RAS(ON) pipeline.· November 4, 2026
- Daraxonrasib generated $198 million in net product revenue in the quarter, driven by more than 5,000 unique commercial patients over about 5 weeks of launch activity.
- The launch started with broad payer access: reimbursed claims across plans covering more than 90% of U.S. PDAC-covered lives, though formal coverage policies are still developing.
- NCCN expanded recommendations for Daraxonrasib in pancreatic cancer and also included it as a category 2a targeted option in metastatic RAS-mutant NSCLC, supporting broader physician awareness.
- Management said the launch is still too early to judge normalized demand, because the quarter included EAP-to-commercial transitions and a backlog of patients waiting for approval.
- The company continues to push a broad pipeline, including multiple phase 3 studies in pancreatic cancer, NSCLC, and colorectal cancer, plus earlier-stage RAS(ON) programs.
Revolution Medicines reported Q3 net product revenue of $198 million from Daraxonrasib, reflecting approximately 5 weeks of U.S. commercialization and initial stocking into the channel. The company ended the quarter with less than 2 weeks of inventory in the channel; it expects long-term channel inventory to stay around 2 weeks. Gross-to-net discount was at the low end of the anticipated 20% to 30% range, and management expects it to rise within that range as payer mix and discounts mature. Cost of sales was $300 thousand, R&D expense was $417 million versus $263 million a year ago, SG&A was $153 million versus $52.8 million a year ago, and net loss was $408 million versus $305 million a year ago; the net loss included a $40.7 million noncash charge tied to warrants. Cash, cash equivalents, and marketable securities totaled $3.7 billion at quarter-end, excluding an additional $250 million received after quarter-end. For full-year 2026, management reiterated GAAP operating expense guidance of $2.1 billion to $2.2 billion, including expected stock-based compensation of $270 million to $290 million. Management also said full-year 2027 GAAP operating expenses should increase from the current run rate, but did not give a specific range.
Mark Goldsmith framed the quarter as a transformational one, centered on FDA approval of Daraxonrasib and the start of commercial delivery to patients with metastatic pancreatic cancer. He emphasized that NCCN guideline recognition, the EMA CHMP positive opinion, and breakthrough therapy designation for the chemo combination all reinforce the drug’s potential role in pancreatic cancer and beyond. His tone was confident and expansive, stressing a multi-asset RAS(ON) strategy across pancreatic cancer, NSCLC, colorectal cancer, and earlier-stage programs, plus collaborations that broaden development capacity and combination options.
Jack Anders focused on the financial mechanics of the launch and the company’s funding position. He said revenue was affected by a partial quarter and initial stocking, gross-to-net was at the low end of the 20% to 30% range, and channel inventory ended at less than 2 weeks, with a long-run target of about 2 weeks. He also highlighted the balance sheet: $3.7 billion in cash, cash equivalents, and marketable securities at quarter-end, plus $250 million received after quarter-end from Royalty Pharma; the company chose not to draw an optional third royalty tranche because of its strong cash position and the future royalty cost that would come with it. He reiterated full-year 2026 GAAP operating expense guidance of $2.1 billion to $2.2 billion, including $270 million to $290 million of stock-based compensation, and said 2027 operating expenses should rise as commercialization and portfolio investment expand.
Analysts focused on how durable the early sales launch is versus one-time backlog, with management explaining that early demand came from three cohorts: patients moving off the expanded access program, patients who had been waiting for approval, and newly eligible patients. On stocking, management said the quarter included initial inventory build and that long-term channel inventory should be around 2 weeks. Questions about community versus academic uptake drew a response that about 40% of use came from academic centers and 60% from community practices, with approximately 2.7 thousand unique prescribers in the quarter. On payer/access concerns, management said claims were reimbursed across plans covering more than 90% of U.S. PDAC lives and that they are not seeing anything unexpected, though formal policies are still rolling out. Analysts also pressed on chemo-free frontline strategy, ORR-based filing ideas, and colorectal trial design; management said overall survival remains the key endpoint, that the ongoing phase 3 studies already include PFS and OS, and that CRC expansion will be data-driven.
The quarter showed a very rapid commercial start, with substantial early revenue and more than 5,000 patients reached in roughly five weeks, alongside broad prescriber uptake and strong payer access. Management also pointed to multiple catalysts ahead: European approval timing, more pancreatic and NSCLC phase 3 progress, colorectal expansion, and additional combination data readouts.
Management repeatedly said it is too early to infer the normalized sales trajectory, and early demand included finite launch dynamics such as EAP conversions and patients waiting for approval. Gross-to-net is expected to rise from the low end of the 20% to 30% range as payer mix matures, and expenses are set to climb further in 2027 as commercialization and the broader pipeline expand.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 90.1%
- Shares Outstanding
- 216.29M
- Float Shares
- 194.80M
of shares held by institutions
740 13F filers
Buy/sell ratio 0.26. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 16.72M | ▲ 1.06M |
| Fmr LLC | 15.40M | ▲ 3.20M |
| Blackrock, Inc. | 13.86M | ▲ 161.53K |
| Farallon Capital Management, L.L.C. | 13.55M | ▼ 54.00K |
| Baker Bros. Advisors LP | 11.44M | ▲ 1.89M |
| Jupiter Topco LLC | 10.74M | ▲ 10.74M |
| Darwin Global Management, Ltd. | 10.63M | ▲ 8.42M |
| Janus Henderson Group Ltd. | 9.77M | ▼ 2.54M |
| Vanguard Capital Management LLC | 9.15M | ▲ 60.87K |
| Vanguard Portfolio Management LLC | 8.16M | ▼ 137.78K |
| Nextech Invest Ltd. | 7.60M | 0 |
| Paradigm Biocapital Advisors LP | 6.36M | ▼ 294.38K |
Held by 1,099 ETFs
Biggest fund positions in RVMD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Kelsey Stephen Michael | other | 27,160 |
| Nov 16, 26 | Kelsey Stephen Michael | sell | 11,542 |
| Nov 16, 26 | Kelsey Stephen Michael | sell | 3,627 |
| Nov 16, 26 | Kelsey Stephen Michael | sell | 8,039 |
| Nov 16, 26 | Kelsey Stephen Michael | sell | 3,052 |
| Nov 16, 26 | Kelsey Stephen Michael | sell | 700 |
| Nov 16, 26 | Kelsey Stephen Michael | sell | 200 |
| Nov 16, 26 | Kelsey Stephen Michael | other | 27,160 |
| Nov 13, 26 | Borellini Flavia | other | 2,500 |
| Nov 13, 26 | Borellini Flavia | other | 2,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RVMD coverage
Recent articles, reports, and earnings notes.

Revolution Medicines (RVMD): RASONQUE Launch Drives Growth
Revolution Medicines has crossed into commercial oncology with a strong RASONQUE launch, but heavy losses and a rich valuation keep the stock at Hold. The pipeline and clinical data support the long-term story, yet near-term upside looks balanced against execution risk.

Revolution Medicines, Inc. (RVMD) drops 6.4% after earnings
Revolution Medicines, Inc. (RVMD) drops after investors digest its latest earnings and strong early RASONQUE launch. The stock’s decline reflects profit-taking, valuation pressure, and broader biotech weakness despite solid revenue growth and encouraging commercial traction.

What to Watch as BlossomHill Therapeutics Prices Its NASDAQ IPO
BlossomHill Therapeutics, Inc. (NASDAQ: BLSM) is expected to list on 2026-08-07 at a price range of $15.00 to $17.00 per share. The company is offering 7,812,500 shares, implying a market cap of $152,734,375 if priced at the midpoint assumptions provided. The bull case is a focused oncology pipeline with named clinical programs and a seasoned drug-discovery team. The bear case is straightforward: no product revenue, rising losses, and a going-concern warning if it cannot raise more capital.
Want a deeper read on RVMD?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Revolution Medicines Drugged a Target Scientists Called “Undruggable” for Decades. Buy the Stock Hand Over Fist?
fool.com · Nov 20
Erasca Throws Down A Gauntlet — And Revolution Throws It Right Back
investors.com · Nov 20
Revolution Medicines Highlights Strong 12-Month Overall Survival Rate for Lead Cancer Drug Regimen
benzinga.com · Nov 20
Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026
globenewswire.com · Nov 19
Revolution Medicines Wins EU Nod for Rasonque in Pancreatic Cancer
zacks.com · Nov 17
European Commission Approves Revolution Medicines' RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
globenewswire.com · Nov 16
Revolution Medicines, Inc. (RVMD) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 16
Revolution Medicines, Inc. $RVMD Stock Acquired by Aberdeen Group plc
defenseworld.net · Nov 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 19, 2026 · Live quote · Not investment advice